News Archive
labforward merges with LabTwin
Expanded possibilities for laboratory digitalization and connectivity
The two Berlin-based companies labforward and LabTwin, a subsidiary of the life science group Sartorius, are merging in order to be able to offer a significantly expanded portfolio of AI and voice-supported solutions for digitalization, connectivity and workflow optimization in the laboratory environment under the name labforward.
Joachim Rautter @ BIG UP 2024
According to the organisers, the start-up festival aims to bring together the entire start-up scene in northern Germany. 24 start-ups are to present themselves and the aim of the event is to bring investors and founders together.
PVP Advisors is looking for you
If you would like to work with us and are interested in a student job, please get in touch!
Longevity Week Berlin
Longevity Week aims to establish Berlin as leading ecosystem for longevity and healthy aging
CryoTherapeutics announces €10 Million Series B extension round
CryoTherapeutics announces €10 Million Series B extension round and promising clinical data for its innovative cryotherapy system to prevent heart attacks
Read more … CryoTherapeutics announces €10 Million Series B extension round
Successful exit for PVP: Cytiva buys our portfolio Company CEVEC
CEVEC is now part of Cytiva
Read more … Successful exit for PVP: Cytiva buys our portfolio Company CEVEC
Miracor Medical - New PiCSO Publication
Microvascular dysfunction after successful primary PCI is frequent and contributes to poor outcomes in STEMI.
RZNOMICS advance its lead compound, a gene therapy produced using CEVEC's CAP® Ad Technology, into clinical development
CEVEC’s license partner RZNOMICS Inc. receives approval to initiate clinical development of CAP® Ad Technology-produced gene therapy vector in liver cancer patients
Miracor Medical starts 2nd randomized study, targeting expanded indications
300 patients have been treated with PiCSO®
Read more … Miracor Medical starts 2nd randomized study, targeting expanded indications
CryoTherapeutics receives additional funding and launches a new clinical study
CryoTherapeutics, focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks, announces today that it has received additional funding of € 12.3 million.
Read more … CryoTherapeutics receives additional funding and launches a new clinical study